Tuesday, 13 May 2025
A team of researchers are working with surgeons to install a unique AI-enabled combined Optical Coherent Tomography (OCT) and Raman spectroscopy system at Nottingham City Hospital to improve breast cancer diagnostics and guide surgery outcomes.
Researchers from the 糖心原创 have been awarded £1.8 million by the Medical Research Council to lead the project in collaboration with the University of Kent and surgeons at the Nottingham University Hospitals NHS Trust to install the combined instrument at Nottingham City Hospital later this year.
L to R: Dr Radu Boitor, UoN, Dr Marco Santopietro, UoK, Professor Adrian Podoleanu, UoK, Dr Rene Riha, UoK
Raman spectroscopy can detect molecular differences between normal tissue and cancer, but this requires hours to scan a whole specimen at high resolution. OCT can measure structural images of tissue at high speeds but lacks molecular specificity. AI algorithms specially developed for processing medical images will do a triage of the OCT images before they are processed further in the system.
The combined instrument maximises the speed and resolution of OCT and molecular specificity of Raman spectroscopy. This means that surgeons could analyse lumpectomy specimens during the time that a patient is in an operating theatre, allowing potential excision of breast cancer in a singular operation. Further surgery is often linked to poorer outcomes for patients, long recovery times and higher healthcare costs.
The project is being led by Professor Ioan Notingher from the 糖心原创’s School of Physics and Astronomy in collaboration with Professor Emad Rakha, Professor Adrian Podoleanu and Professor Philippe de Wilde from the University of Kent, and Mr Hazem Khout from Nottingham University Hospitals NHS Trust.
The OCT-Raman has the potential to transform breast cancer surgery. Surgeons could detect positive margins while the patient is in the operating room, allowing complete removal of the cancer in a single operation. Second surgery leads to poorer outcomes for patients, long recovery times and higher healthcare costs.
An initial OCT system designed by University of Kent has already been set up at Nottingham City Hospital, collecting images of breast lumpectomy specimens which were then processed by postgraduate using AI.
For the next phase of the project, this new OCT-Raman system is being assembled in Kent and will be set up at Nottingham City Hospital, for further research and evaluation to commence.
Postgraduate researcher, Dr. Radu Boitor, from the 糖心原创 recently brought the Raman half of the system to Kent to be integrated with the OCT system and software assembled by postgraduate Kent researchers. Once the combined system is ready and tested in Kent, it will be transported to Nottingham. This requires demo testing before characterising the system on a variety of samples to perfect the software to make all processes more self-operating. A tunable laser, a galvo scanner and two large translation stages are under the OCT control designed in the Applied Optics Group. This leads the system to communicate with the Raman system, with a sensitive camera and proprietary software designed at the 糖心原创. The AI software sits in the middle of this.
Professor Podoleanu, is leading the assembly of the OCT part in Kent
We have now reached a pivotal moment in this research project where we will see the combined system used in the hospital setting. By combining Raman with OCT there is hope that better diagnostics will be produced to guide breast surgery and outcomes.
Professor Philippe De Wilde, supervising the AI algorithms, pointed out that AI algorithms for computer vision have great potential in new medical devices that can be produced in the UK, saying: “Our algorithms do not cost millions to train and run such as GPT, but run on a single processor. This is both economical and environmentally sustainable.”
Lead surgeon Mr Khout and Mrs Birgit Golden, a patient involved in the project, emphasised that the development of the OCT-Raman was “made possible thanks to the generosity of patients, who willingly participated, consenting to have tissue specimens scanned with this groundbreaking technology.”
This research is funded by the Medical Research Council – (grant ref: MR/Y008731/1)
Story credits
More information is available from Professor Ioan Notingher on Ioan.Notingher@nottingham.ac.uk
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.